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Background: Postpartum haemorrhage (PPH) is a leading cause of maternal mortality especially 
in the developing world. Misoprostol, a highly effective drug is highly effective in inducing 
uterine contractions and has been proposed as a low-cost, easy-to-use intervention for PPH.
Objective: This study assessed evidence of the effectiveness of misoprostol for the prevention 
and treatment of PPH.
Method: Databases searched included MEDLINE, PUBMED, CINHAL, Google Scholar, Cochrane 
Central Register of Controlled Trials (CENTRAL) and EMBASE. Reference lists and conference 
proceedings were also searched for more studies. Three studies included in the meta-analysis 
were limited to randomised controlled trials (RCT). Two reviewers independently screened all 
articles for methodological quality using a standardised instrument adapted from the Cochrane 
Collaboration website. Data were entered in Review Manager 5.1 software for analysis.
Results: Three trials (n = 2346) compared misoprostol to a placebo. Misoprostol was shown not to 
be effective in reducing PPH (risk ratios [RR] 0.65; 95% confidence interval [CI] 0.40–1.06). Only 
one trial reported on the need for a blood transfusion (RR 0.14; 95% CI 0.02–1.15). Shivering 
(RR 2.75; 95% CI 2.26–3.34) and pyrexia (RR 5.34; 95% CI 2.86–9.96) were significantly more 
common with misoprostol than with a placebo.
Conclusion: The use of misoprostol was not associated with any significant reduction in the 
incidence of PPH. Therefore, in order to verify the efficacious use of misoprostol in the treatment 
of PPH, specialised investigations of its dose and routes of administration for clinically 
significant effects and acceptable side effects are warranted. 
Introduction
Maternal mortality continues to be one of the most serious and intractable health problems 
for women of reproductive age in low-income countries (Tsu & Shane 2004:83). To reduce the 
maternal mortality ratio by three quarters by 2015 is the target for one of the eight Millennium 
Development Goals (MDGs) set by 189 countries in 2000 (Rosenfield, Maine & Freedman 
2006:1333). Postpartum haemorrhage (PPH), the leading cause of maternal deaths worldwide, 
has been receiving increased attention amongst medical researchers for the last few decades. The 
World Health Organization (WHO 2007) defines PPH as postpartum blood loss of 500 mL or 
more from the genital tract. However, in populations with a higher prevalence of anaemia, blood 
loss of less than 500 mL has been reported to have several physical consequences (McCormick 
et al. 2002:267). 
Statement of the problem
The maternal mortality ratio in developing countries is 450 maternal deaths per 100 000 live 
births versus nine in developed countries (WHO 2007). An estimated 358 000 maternal deaths 
occurred worldwide in 2008 (UNICEF 2010). According to UNICEF (2010), out of 1000 maternal 
deaths due to severe bleeding after childbirth, 560 deaths occurred in sub-Saharan Africa and 
300 in South Asia compared to five in high-income countries. According to the Millennium 
Development Goals (MDGs) report (2010), there was a significant reduction in maternal mortality 
ratios (MMRs) in developing regions. The average annual percentage decline in the global MMR 
was 2.3% - short of the MDG target of 5.5%. However, in 2008 in sub-Saharan Africa, where levels 
of mortality were highest, there was an estimated 1.7% annual rate of decline - slower than in any 
other region. According to UNICEF (2010), the maternal mortality ratio in South Africa was 410 
in 100 000 live births in 2008. 
The Saving Mothers report (2007:12) states that obstetric haemorrhage is the third most common 
cause of maternal death in South Africa (SA), accounting for 491 (12.4%) of all maternal deaths during 
the period from 2005 to 2007. Substandard care remained a major problem in SA, contributing 
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to over 40% of deaths for every level of care. This includes 
failure to carry out essential steps of prescribed protocols, 
or serious delays in doing so, and lack of appropriate skills. 
According to Fawcus and Moodley (2011), it is fundamental 
that all levels of care are able to deal with the emergency 
management of PPH and are aware of the factors required 
to prevent it. This necessitates sufficient facilities, supplies 
and skilled staff. Major improvements in the implementation 
of the health system and appropriate training of doctors and 
midwives at all levels of care are essential if deaths from this 
preventable cause of maternal mortality are to be reduced. 
Aetiology of postpartum haemorrhage: PPH results mainly 
from uterine atony. Pillitteri and Klweri (2010:677) state that 
correlates such as multiple gestation, hydramnios, macrosomic 
baby, presence of uterine myomas, operative birth, rapid 
birth, placenta praevia, placenta abruption, retained placenta 
fragments, secondary maternal illness, prolonged use of 
magnesium sulphate or tocolytic therapy, disseminated 
intravascular coagulation and high parity predispose women 
to uterine atony. Other aetiologies include coagulation 
defects, retained placenta and trauma.
Description of intervention
Weeks and Faúndes (2007) delineate misoprostol as a 
prostaglandin E
1
-analogue with uterotonic properties that 
can be administered orally, sublingually, vaginally and 
rectally. Sublingual administration of misoprostol achieves 
the uppermost serum peak absorption and takes the shortest 
time to reach the peak level in comparison with other routes 
of administration (Tang et al. 2002). Initially, misoprostol 
was introduced as treatment for peptic ulcers. Misoprostol 
has been used to treat a variety of obstetrical problems, 
including uterine atony, postpartum haemorrhage, the 
induction of labour and the induction of abortion (Hofmeyr 
et al. 2005). Ng et al. (2001) observed that misoprostol, 
when given postpartum, is known to cause only mild side 
effects (shivering and pyrexia). However, misoprostol is 
a sustainable drug for use in developing countries for the 
treatment of an assortment of obstetrical complications 
(Winikoff et al. 2010). 
How misoprostol might work
The key management of PPH involves rapid recognition 
and diagnosis of the condition, as well as restoration of 
circulating blood volume with a simultaneous search for 
the cause. According to WHO (2000), injectable oxytocin 
and ergometrine have been recommended for routine 
use in the active management of the third stage of labour. 
However, the administration of an injection requires skills 
and sterile equipment for safe administration. Oxytocin may 
be inactivated if exposed to high ambient temperatures and 
requires cold-chain storage. WHO (2000) regard oxytocin as 
the gold standard for treatment of postpartum haemorrhage. 
Mousa and Alfirevic (2007) state that misoprostol is highly 
effective in inducing uterine contractions and has been 
proposed as a low-cost, easy-to-use alternative to oxytocin. 
Oxytocin is usually the preferred drug where active 
management of the third stage of labour is practised 
(Gülmezoglu et al. 2001; Langenbach 2006). Zuberi et al. (2008) 
advocated for the availability of misoprostol in community-
based settings with limited access to conventional injectable 
uterotonics. Misoprostol has an important role to play in 
hospital settings and its adjunct use should continue to be 
explored for its potential in the quick, safe and effective 
controlling of postpartum bleeding, averting recourse to more 
invasive procedures and preventing more severe maternal 
morbidity (Zuberi et al. 2008). Ng et al. (2001) observed that 
when misoprostol is given postpartum it produces only mild 
side effects (shivering and pyrexia), which are dose-dependent. 
Significance of this research
Although there are several interventions for prevention 
and treatment of PPH, the results of most studies on use of 
misoprostol for PPH are contradictory. Several systematic 
reviews have assessed the effectiveness of misoprostol in 
the prevention of PPH (Gülmezoglu et al. 2011; Hofmeyer et 
al. 2005; Langenbach 2006; Mousa & Alfirevic 2007). These 
reviewers looked at the possibility that misoprostol can be used 
as first-line of therapy in the absence of injectable uterotonics. 
However, the results of some of the aforementioned reviews 
do show the significance of misoprostol in the prevention 
and treatment of PPH. Furthermore, these reviews included 
studies that compared misoprostol to a placebo in addition 
to standard uterotonics used in routine practice. Thus, the 
question arises whether the real effectiveness of misoprostol 
used in the third stage of labour is affected by its combined use 
with additional uterotonics. A systematic review is therefore 
needed to collate and assess the effectiveness of misoprostol 
alone (i.e. without other uterotonics) compared to a placebo 
for the prevention and treatment of PPH, particularly in cases 
where other uterotonic agents are not feasible. 
Objectives 
The objective of this systematic review was to assess evidence 
on the effectiveness of misoprostol compared to a placebo for 
the prevention and treatment of PPH. 
Specific objectives: The specific objectives were to determine 
the effectiveness of misoprostol in preventing and treating 
blood loss of ≥ 500 mL and to investigate maternal mortality 
and severe morbidities associated with the use of misoprostol 
compared to a placebo for the prevention of PPH. 
Research methods and design
Criteria for considering studies for this review
Types of studies: Randomised controlled trials (RCT) that 
assessed the effectiveness of misoprostol compared to a 
placebo in the prevention and treatment of PPH during 
vaginal delivery were included in this review. 
Types of participants: Studies that included women in 
labour with anticipated vaginal deliveries, with no history 
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of postpartum haemorrhage, at low risk of PPH and with 
singleton pregnancies were considered for inclusion. Studies 
that included women with Caesarean section and women with 
anaemia were excluded as such participants are considered to 
be high-risk pregnancies and vulnerable to PPH.
Types of interventions: Interventions considered for this 
review were misoprostol versus a placebo, or non-treatment, 
for the prevention and treatment of PPH up to the third 
stage of labour. All studies, irrespective of dose or route 
(oral, sublingual or rectal) of misoprostol administration 
were considered for this review. Studies that compared 
misoprostol to a placebo in addition to other uterotonics 
were excluded.
Types of outcomes measured 
Primary outcomes
Outcomes of interest in trials:
•	 Blood loss of 500 mL
•	 Maternal mortality
Secondary outcomes
•	 Severe morbidity (hysterectomy and/or surgery, need for 
blood transfusion and manual removal of placenta).
•	 Pyrexia (temperature of ≥ 38 °C) and severe side effects 
(vomiting and shivering).
•	 Need for additional use of uterotonics.
For the purpose of this review, maternal morbidity was 
defined as the need for a blood transfusion, manual removal 
of the placenta, hysterectomy and major surgery, and pyrexia 
was defined as a temperature equal or greater than 38 °C.
Electronic search
A comprehensive search for relevant studies was conducted 
on the following databases: MEDLINE (Medical Literature 
Analysis and Retrieval System Online), PUBMED, CINHAL 
(Cumulative Index of Nursing and Allied Health), Google 
Scholar, Cochrane Central Register of Controlled Trials 
(CENTRAL) and EMBASE. Subsequent MeSH (Medical 
Subject Headings) terms used were misoprostol, ergot 
preparations, prevention, postpartum haemorrhage and 
randomised controlled trials. The search strategy used was 
misoprostol or cytotec or placebo, and RCT or random 
or controlled trials, and prevention or treatment, and 
postpartum haemorrhage or PPH. The search was conducted 
irrespective of geographical region of the study. 
Searching other sources
A list of hand-searched (pearling) journals, textbooks and 
conference proceedings were examined for more studies. 
WHO Drug Administration Guidelines were also considered. 
Professor Hofmeyr, a specialist in obstetrics, gynaecology 
and midwifery, was consulted for input and appraisal of the 
main objective of this review. 
Data collection and analysis
Selection of studies 
The search yielded 339 articles. After careful reading of the 
titles, 294 articles were rejected. The abstracts of the remaining 
45 articles were independently read by two reviewers, Kabelo 
Monicah Olefile (KMO) and Oswell Khondowe (OK). Thirty-
six articles were excluded as they did not meet the inclusion 
criteria. The reasons for exclusion were that articles were 
reviews, editorials, reporting on outcomes not of interest, 
misoprostol being administered for other obstetrical uses 
and misoprostol being compared to other uterotonic drugs. 
The reviewers independently read the remaining full-text 
nine articles. This procedure led to the further exclusion 
of six articles based on the reasoning that misoprostol was 
compared to a placebo in addition to other uterotonics. This 
study therefore included three articles. See Figure 1 for the 
selection of articles.
Data extraction and management
Reviewers independently extracted data from the studies by 
using a standardised data extraction form that was adapted 
from the Cochrane Collaboration website. It was adjusted and 
refined for the purpose of this review. The refined version was 
piloted and used in the research process by Kabelo Monicah 
Olefile (KMO) and Oswell Khondowe (OK). Data were 
entered into Review Manager 5.1 (RevMan 5.1) for analysis.
Assessment of risk of bias in included studies 
It is important to systematically complete a critical appraisal 
of all the studies in a review to prevent flaws, even if there is 
no variability in either the validity or results of the included 
studies (Higgins & Green 2006). The validity of each study 
Potentially relevant studies identified
and screened for retrieval (n = 339).
Studies retrieved for more detailed
evaluation (n = 45).
Studies excluded after reading titles 
(n = 294).
• Duplicates
• Reviews
Studies excluded after reading 
abstracts (n = 36). Reviews, case 
reports, studies not reporting on
outcome of interest, commentaries, 
books. Misoprostol compared to 
other uterotonic drugs.
Studies excluded after full text evaluation 
and methodological assessment (n = 6).
• Unblinded, outcomes not clearly 
reported, attrition rate of more than 
15%.
• Interventions used in addition to 
other uterotonic drugs.
Studies included in systematic review (n = 3).
Potentially appropriate studies to 
be included in the systematic
review and meta-analysis (n = 9).
FIGURE 1: Flow diagram of electronic search.
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was assessed using the criteria outlined in the Cochrane 
Collaboration ‘risk of bias’ quality assessment tool. To 
determine the selection bias and performance bias, quality 
scores for allocation concealment and blinding were classified 
as follows: (1) low risk if a method such as consecutively 
numbered, sealed, opaque envelopes were used, (2) unclear if 
the concealment method was not described or (3) high risk if 
an open list of random records, case record numbers, dates of 
birth or days of the week were used. Allocation concealment 
was considered adequate in all three included studies as 
sealed envelopes, opaque containers or identical numbered 
boxes containing identical trial medications were used. In 
one trial, traditional birth attendants carried out the trial, the 
allocation of interventions was not stated and relevant data 
for analysis were not recorded (Prata et al. 2005).
For attrition bias due to loss to follow-up, protocol deviations, 
withdrawals and dropouts, completeness was assessed by 
looking at the percentage of participants lost. Studies were 
considered to be unbiased if the loss of participants was less 
than 15%. In the trial described by Derman et al. (2006), a total 
of four women (attrition rate of 0.25%) did not receive the 
trial treatments, but were included for analysis. In the other 
two trials included in this study (Hoj et al. 2005; Suberk et al. 
1999) there was no loss of participants.
The assessment of PPH has a potential bias if the researchers 
making the assessments are not blinded to the intervention. 
In this review, double blinding was confirmed in three 
included studies, but in Prata et al. (2005) blinding was not 
preformed. The three trials clearly described the methods 
of blood measurement used in both intervention groups. 
However, errors are likely to be distributed equally between 
the two study groups and are unlikely to have introduced 
any systematic bias that could have affected the significance 
of the study results. The article highlighted in grey in Table 1 
was excluded after methodological assessment.
Measures of treatment effect
Summarised results were presented using risk ratios (RR) 
with a 95% confidence interval (CI) as the measurement of 
effect size for binary outcomes. For continuous data (mean 
blood loss) weighted mean differences were not calculated, 
as outcomes were not measured in the same way between 
trials. Random effect meta-analysis (the Mantel-Haenszel 
method) was used, as the trials were heterogeneous. 
Statistical analysis was carried out using Review Manager 
5.1 (RevMan 5.1). 
Dealing with missing data 
Reviewers proposed to contact the original authors in cases 
where data were missing. However, this was not necessary, 
as all required data were obtainable in the included articles. 
Assessment of heterogeneity 
A test of heterogeneity between trials was applied by 
using I ². If the I ² was between 0 and 30% it was interpreted 
as mild heterogeneity. If the I ² was between 30% and 60% it 
represented moderate heterogeneity, 50% – 90% represented 
substantial heterogeneity and 75% – 100% was considerable 
heterogeneity. The Chi-square test was used for the power 
of the studies and a p-value of ≤ 0.05 was used to detect 
significant difference amongst studies. A random-effects 
meta-analysis (the Mantel-Haenszel method) was used. 
Assessment of reporting bias
All three trials were included for meta-analysis and were 
investigated for reporting bias. Reporting bias was not 
identified in any of the included studies. Funnel plots 
parallel to meta-analysis of the primary outcomes were used 
in assessing publication bias.
Data synthesis
All outcomes in this review were presented as binary data. 
Meta-analysis was performed using RevMan 5.1 software. 
Random-effects meta-analysis (the Mantel-Haenszel method) 
was used to calculate the pooled estimate. A 95% confidence 
interval was calculated for each effect size estimate. 
Heterogeneity was measured with the I ² test and the Chi-
square test with a p-value of less than 0.05 to indicate a 
significant difference amongst studies. Forest plots were 
used to reveal the effect of interventions. Sub-group analysis 
was intended to further explore heterogeneity. 
Sub-group analysis and investigation of 
heterogeneity 
Sub-group analysis was a priori based on the dose administered 
and the route of administration. However, sub-grouping 
was being carried out on the route of administration. All 
included trials used a dose of 600 μg. Two trials, Derman et al. 
(2006) and Suberk et al. (1999), administered misoprostol 
orally and in Hoj et al. (2005) misoprostol was administered 
sublingually.
Table 2 shows the results of studies sub-grouped according to 
route of administration (orally and sublingually). There was 
TABLE 1: Assessment of methodological quality: Risk of bias.
Study Sequence allocation Allocation concealment Blinding Incomplete outcome 
data
Selective outcome reporting Potential 
threats
Attrition 
rate (%)
Derman 2006 LR-Computer generated LR-Sealed envelopes LR-Double blinding LR-No data missing LR-All outcomes reported U 0.25
Hoj 2005 HR-Random list of numbers LR-Opaque envelopes LR-Double blinding LR-No data missing LR-All outcomes reported U 0.0
Prata 2005 HR-Not described HR-Not described HR-Not blinded HR-Some outcomes 
not reported
HR-Some outcomes 
not reported
U 17.5
Surbek 1999 LR-Random number 
generated tables
LR-Identical gelatine capsules, 
opaque sealed envelopes
LR-Double blinding LR-No data missing LR-All outcomes reported U 0.0
LR, low risk; HR, high risk; U, unclear.
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no evidence of heterogeneity amongst studies. The results of 
all the studies were combined for meta-analysis.
Sensitivity analysis
It was pre-specified that a sensitivity analysis would be 
performed on the quality of the included studies, excluding 
trials where allocation concealment is inadequate. 
Reliability and validity
Reviewers performed the assessment of the studies 
independently, using a standardised data extraction form. 
Both reviewers are trained in research methodology and OK 
has published systematic reviews previously.
Results
Results of the search
A search of databases and hand-searching of other literature 
sources yielded 339 unique citations. One reviewer (KMO) 
examined the titles and abstracts and identified 45 reports 
as potentially relevant. These were then independently 
screened by KMO and OK. Four studies were assessed for 
methodological quality and one study was then excluded. 
Three studies were included for meta-analysis of this review.
Description of studies
See Table 3 for the characteristics of the included studies.
Included studies: Three studies with a total of 2346 participants 
were included. The important characteristics of the included 
studies are summarised in Table 3. The trials compared the 
effectiveness of misoprostol to a placebo for the management 
of the third stage of labour in pregnant women with vaginal 
delivery. All trials used 600 μg misoprostol tablets. Two trials, 
Derman et al. (2006) and Suberk et al. (1999), administered 
misoprostol orally and in the Hoj et al. (2005) trial misoprostol 
was administered sublingually. The average age for participants 
was 23.3 years amongst all included trials. The trials were 
conducted in three different countries: Derman et al. (2006) 
in India, Hoj et al. (2005) in Guinea Bissau and Suberk et al. 
(1999) in Switzerland. Treatment interventions were given 
immediately after the delivery of the baby. Not all of the 
trials measured all outcomes identified for this review, but 
the main outcomes were presented.
Excluded studies: Thirty-six out of 45 reports were retrieved 
for further assessment and were excluded after reading the 
abstracts. Nine studies appeared to be eligible for inclusion 
in this review. However, six trials were excluded after full-
text examination. In one trial the methodological quality was 
poor, the unblinded outcomes were not clearly reported, 
there was an attrition rate of more than 15% and there 
was no randomisation. Five trials were excluded because 
misoprostol was compared to a placebo in addition to other 
uterotonics. One trial, Prata et al. (2005), was then excluded 
after the assessment of risk of bias.
Risk of bias in included studies
The two reviewers (KMO & OK) assessed all of the 
included trials for risk of bias and were blinded to each 
other’s assessments. Disagreements were resolved through 
discussions. Domains from the Cochrane Collaboration 
risk of bias tool were assessed for each trial. Risk of bias is 
detailed for each trial in the the ‘risk of bias summary’ (see 
Figure 2). In addition, an overall assessment of risk of bias 
can be viewed in Figure 3. 
Allocation (selection bias)
The way in which comparison groups are assembled is an 
important factor that may lead to selection bias if not applied 
accordingly. Random sequence generation was rated as 
low risk if every participant had an equal chance of being 
selected for either condition or if the researchers were unable 
to predict the treatment group the participant was assigned 
to. The use of date of birth, date of admission and date of 
the week, or alternation resulted in labeling a study as high 
risk of bias. Allocation concealment was assigned to be low 
risk if the methods to conceal allocation, such as central 
TABLE 2: Subgroup analysis on route of administration.
Outcomes Orally Sublingually
Combined RR  95% CI Combined RR  95% CI
Incidence of PPH 
(blood loss ≥ 500 mL)
0.52  0.38 0.72 0.89  0.76 1.04
Pyrexia 3.76  1.81 7.79 7.11  3.85 13.12
Shivering 2.98  2.53 3.51 2.43  1.96 3.01
RR, risk ratios; CI, confidence interval.
Sublingually, 1 study; orally, 2 studies.
TABLE 3: Characteristics of included studies.
Author Methods Design Participants Interventions Outcomes 
Derman 2006 •	 Randomisation 
and concealment 
by computer 
generated list with 
a random block size
•	 Sealed envelopes
•	 Double blinding
•	 Randomised 
controlled trial
•	 1620 pregnant 
with anticipated, 
uncomplicated 
spontaneous 
vaginal delivery
•	 600 μg oral misoprostol 
versus identical placebo
•	 Primary outcome: the incidence of acute postpartum 
haemorrhage (blood loss ≥ 500 mL). 
•	 Secondary outcomes: severe postpartum haemorrhage 
(blood loss ≥ 1000 mL within 2 hours of delivery) and mean 
blood loss, need for transfer to a higher level facility, use of 
additional open-label uterotonic agents, blood transfusion, 
surgical intervention, maternal death, and drug-related 
maternal and neonatal side-effects
Hoj 2005 •	 Randomisation by 
opaque envelopes 
were consecutively 
numbered
•	 Randomised 
double blinding
•	 Placebo 
controlled trial
•	 661 women 
undergoing 
vaginal delivery
•	 Misoprostol 600 μg 
or identical placebo 
administered sublingually 
immediately after delivery
•	 Incidence of PPH (blood loss of ≥ 500 mL)
•	 Decrease in haemoglobin concentration after delivery
Surbek 1999 •	 Random allocation 
with number-
generated tables
•	 Randomised 
double masked 
placebo-
controlled trial
•	 65 women with 
anticipated 
vaginal deliveries
•	 Oral dose of misoprostol 
(600 μg) versus identical 
placebo immediately after 
cord clamping
•	 Primary outcome: incidence of PPH (blood loss ≥ 500 mL) 
and by antepartum and postpartum hematocrit values
•	 Secondary outcomes: side effects, additional use of 
oxytocics
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randomisation, serially numbered, opaque, sealed envelopes 
and other descriptions with convincing concealment, were 
used. Concealment of allocation was considered high risk if 
alteration methods were used and unclear if authors did not 
adequately mention the concealment. 
Blinding (performance bias and detection bias) 
The blinding of outcome assessors to the intervention 
allocation reduces detection bias. Blinding of those receiving 
and providing care is useful in protecting against performance 
bias. Blinding was assigned to be low risk if both participants 
and personnel were unaware of the interventions they were 
allocated to. The trial was assigned to be at high risk of bias 
if participants, personnel and outcome assessors were not 
blinded to the intervention group. Blinding was considered 
to be unclear if participants, personnel and outcome assessors 
were not mentioned as being blinded to the interventions. 
Incomplete outcome data (attrition bias)
Loss to follow-up was coded in each outcome as follows:
•	 Low risk: if attrition rate was less than 15% and if reasons 
for loss to follow-up were similar in both treatment arms. 
•	 High risk: if more than 15% of patients were lost to follow-
up or reasons for loss to follow-up were not mentioned.
•	 Unclear: if loss to follow-up was not reported.
The proportion of participants whose outcomes were analysed 
was recorded in this review.
Selective reporting (reporting bias) 
Selective reporting is important in areas where multiple 
outcome measures are used (Gotzsche 1989). Specification 
of predefined outcomes and analysis in the trials was 
considered as indicators of validity. Obtaining missing data 
from original investigators can be used to minimize selective 
reporting, but it was not necessary for this trial. The criterion 
below was used to measure reporting bias in the trials: 
•	 Low risk - reports of the study were free of suggestion of 
selective reporting.
•	 High risk - reports of the study suggested selective 
outcome reporting.
•	 Unclear - if analysis was by intention to treat.
Other potential sources of bias 
All of the studies had insufficient information to assess 
whether other important risks of bias existed. Information on 
potential financial conflicts of interest was considered as a 
possible source of additional bias. The criterion below was 
used to give each trial an overall quality rating: 
•	 Low risk of bias - all criteria met.
•	 Moderate risk of bias - one or more of the criteria partly met.
•	 High risk of bias - one or more criteria not met.
Figure 2 presents the trials on the vertical axis in alphabetical 
order and the risk of bias on the horizontal axis. The risk of 
bias assessment was performed in four trials after which one 
trial was excluded due to the high risk of bias in all domains. 
Figure 3 illustrates approximately 75% confirmation of 
allocation concealment, blinding, incomplete data and 
selective reporting in the trials. Random sequence generation 
was addressed in about 50% of the trials. A judgement 
of unclear for other sources of bias, such as declaration of 
conflict of interest, was not reported in any of the trials.
Effects of interventions
Comparison: Misoprostol versus placebo
Incidence of PPH (blood loss of ≥ 500 mL): Three studies 
with a total of 2346 participants reported on incidence of 
PPH, as shown below in Figure 4. There was a non-significant 
tendency of blood loss of ≥ 500 mL for those who received 
misoprostol (RR 0.65; 95% CI 0.40–0.06). Misoprostol does not 
appear to be more effective than a placebo in the treatment 
of PPH. There was a high level of heterogeneity amongst the 
studies (p = 0.008; I 2 = 79%). 
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FIGURE 2: Risk of bias summary: Review authors’ judgements about each risk of 
bias item for each included study.
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Need for blood transfusion: Only one trial, Derman et al. 
(2006), reported on the need for a blood transfusion. The 
study found no significant difference in the need for a blood 
transfusion between participants who received misoprostol 
and placebo (RR 0.14; 95% CI 0.02–1.15). Heterogeneity was 
not applicable as only one trial reported on the need for a 
blood transfussion.
Hysterectomy and surgery: Only one trial (Derman et al. 
2006) reported on hysterectomy or major surgery. The 
overall effect of misoprostol was coupled with a reduced rate 
of hysterectomy/surgery compared to a placebo (RR 0.12; 
95% CI 0.02–0.99; p = 0.05). A test for heterogeneity was not 
computed as there was only one trial for this analysis.
Pyrexia: Figure 5 below illustrates the occurrence of pyrexia 
in two trials. Participants that were given misoprostol had 
a 5.34 times higher probability of experiencing pyrexia 
compared to those who received a placebo. We can be 95% 
confident that the true value of the population lies between 
2.86 and 9.96. There was no evidence of a significant difference 
in the results of the studies included for the outcome pyrexia 
(p = 0.19; I 2 = 42%).
Shivering: Figure 6 shows binary data of three trials with 2346 
participants. Participants that were given misoprostol had a 
2.76 times higher probability of shivering compared to those 
who received a placebo. Misoprostol was not associated with 
a significant reduction in shivering. We can be 95% certain 
that the true value of the population lies between 2.26 and 
3.34. Some evidence of statistical heterogeneity was detected 
in the studies (p = 0.21), but the p-value was insignificant.
Need for additional uterotonics: Figure 7 below shows the 
results of two studies. Participants in the misoprostol group 
showed a 54% reduction in the need for additional uterotonics 
compared to those who received a placebo (RR 0.44; 95% 
CI 0.21–0.95; p = 0.04). The trials were heterogeneous 
(Chi² = 0.04; I ² = 0%; p = 0.84) and there was no significant 
difference amongst all the studies as they strongly favored 
misoprostol with a risk ratio of less than one. 
CI, confidence interval.
FIGURE 4: Random effect analysis of misoprostol versus a placebo in the prevention and treatment of Postpartum haemorrhage on incidence of Postpartum haemorrhage. 
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Total (95% CI) 1173 1173 100.0% 0.65 [0.40 – 1.06]
Total events 204 275
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FIGURE 5: Random effect analysis of misoprostol versus a placebo in the prevention and treatment of Postpartum haemorrhage on pyrexia.
Experimental Control Risk ratio Risk ratio
Study or Subgroup Events Total Events Total Weight M-H, Random, 95% CI M-H, Random, 95% CI
Derman 2006 34 812 9 808 45.1% 3.76 [1.81 – 7.79]
Hoj 2005 78 330 11 331 54.9% 7.11 [3.85 – 13.12]
Total (95% CI) 1142 1139 100.0% 5.34 [2.86 – 9.96]
Total events 112 20
Heterogeneity: Tau2 = 0.09; Chi2 = 1.74, df = 1 (P = 0.19); I2 = 42%
Test for overall effect: Z = 5.26 (P < 0.00001)
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FIGURE 6: Random effect analysis of misoprostol versus placebo in the prevention and treatment of Postpartum haemorrhage on shivering.
Experimental Control Risk ratio Risk ratio
Study or Subgroup Events Total Events Total Weight M-H, Random, 95% CI M-H, Random, 95% CI
Derman 2006 419 812 140 808 55.6% 2.98 [2.53 – 3.51]
Hoj 2005 189 330 78 331 43.5% 2.43 [1.96 – 3.01]
Surbek 1999 7 31 1 34 0.9% 7.68 [1.00 – 58.92]
Total (95% CI) 1173 1173 100.0% 2.75 [2.26 – 3.34]
Total events 615 219
Heterogeneity: Tau2 = 0.01; Chi2 = 3.15, df = 2 (P = 0.21); I2 = 36%
Test for overall effect: Z = 10.14 (P < 0.00001)
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The results of the studies show that misoprostol administered 
either orally or sublingually does not show a significant 
reduction in postpartum blood loss. Side effects, pyrexia and 
shivering were persistent in the misoprostol group, but were 
dose-related. Maternal mortality and manual removal of 
placenta were not reported in any of the studies (n = 3).
Discussion
The purpose of the review was to assess evidence on the 
effectiveness of misoprostol compared to a placebo for the 
prevention and treatment of postpartum haemorrhage. Three 
trials that fulfilled the inclusion criteria were identified. In 
meta-analysis of those three trials, there was a non-significant 
tendency of blood loss of ≥ 500mL for participants who 
received misoprostol (RR 0.65; 95% CI 0.40–1.06). However, 
there was a high level of heterogeneity amongst the studies 
(p = 0.008). These findings are not consistent with the meta-
analysis performed by Hofmeyer et al. (2005) who found a 
pooled risk ratio of 0.57 (95% CI 0.34–0.96). Even though the 
studies that Hofmeyr et al. (2005) included in their meta-
analysis compared misoprostol to a placebo in addition to 
other uterotonic drugs, the results are of great weight. 
There was no incidence of maternal mortalities reported in 
any of the trials in this review. However, in previous trials by 
Hofmeyer et al. (2004) there were three maternal deaths out 
of 117 participants in the misoprostol arm and Widmer et al. 
(2010) reported two maternal deaths out of 705 participants 
in the misoprostol arm compared to a placebo. Despite the 
small number of participants recruited in those two trials, the 
results should be interpreted with great caution. Only one 
trial, Derman et al. (2006), reported on the need for a blood 
transfusion. The study found no significant difference in 
the need for a blood transfusion between participants who 
received misoprostol or a placebo (RR 0.14; 95% CI 0.02–1.15).
As reported in previous trials (Hofmeyr et al. 2004; Hofmeyer 
et al. 2005; Walraven et al. (2004)) shivering and pyrexia 
are centrally mediated with prostaglandin use and was 
significantly more frequent amongst women in the misoprostol 
group than those in the placebo group. In other clinical trials 
by Amant et al. (1999) and El-Refaey et al. (1997) the increase 
in temperature after the administration of misoprostol was a 
common finding. The findings of increased shivering were 
comparable with that reported in literature of Hofmeyer et al. 
(2004), El-Refaey et al. (1997) and Suberk et al. (1999). In the 
Hofmeyr et al. (2004) trial, where 1000 mg misoprostol was 
used, it was stated that the side effects of misoprostol may be 
related to rapid absorption when given orally and elevated 
bioavailability when given sublingual. The side effects do 
not rule out misoprostol for being biologically reasonable to 
use in the treatment and prevention of PPH in the absence of 
conventional uterotonics, as they are dose-related.
There were a total of nine cases of hysterectomy reported in 
one trial, Derman et al. (2006): one in the misoprostol group 
and eight in the placebo group (1620 participants; RR 0.12; 
95% CI 0.02–0.99; p = 0.05). Misoprostol has shown a reduced 
need for additional uterotonics compared to a placebo (RR 
0.45; 95% CI 0.21–0.96; p = 0.04). There was no statistical 
heterogeneity detected amongst the trials (p = 0.84).
Practical implications 
Future randomised controlled trials are required to identify 
the best route and dose of misoprostol for the treatment of 
primary PPH. Home deliveries in some communities are still 
evident. It is vital to investigate interventions to control PPH 
following home deliveries. More importantly, trials must be 
large enough to assess maternal morbidity and mortality. 
There has been a lack of research linking the management of 
the third stage of labour to what has occurred in the first and 
second stages. It may be timely to assess the possible effects 
of current strategies for the management of labour on the 
rates of PPH. None of the included trials has addressed the 
women’s preferences in terms of uterotonic options. It would 
be of interest to embrace this aspect of care in future research 
on trials of uterotonic choice.
Overall completeness and applicability of evidence
This review aimed to discover if misoprostol is more effective 
than a placebo in the prevention and treatment of PPH. 
All relevant literature was retrieved. The included studies 
concentrated on how effective misoprostol is and the body of 
evidence applies to the research question. All main outcomes 
of interest were presented in the trials, but not all of the 
sub-outcomes. 
Quality of evidence
According to Higgins and Green (2006), randomised 
controlled trials are measured gold standard study designs 
to answer a problem on the effectiveness of a particular 
treatment. Therefore trials were restricted to this study 
CI, confidence interval.
FIGURE 7: Random effect analysis of misoprostol versus a placebo in the prevention and treatment of Postpartum haemorrhage on need for additional uterotonics.
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design. The risk of bias was assessed in three of the included 
trials. About 75% of the trials were free from attrition bias, 
detection bias, performances and reporting bias. About 
50% of the trials were free from selection bias. Only trials 
that compared misoprostol to a placebo were considered 
for this review. In all of the trials the treatment was given 
immediately after the delivery of the interior shoulder of the 
baby. Even though the estimation of blood loss is known to be 
difficult and inaccurate, the measurement of blood loss was 
similar in all trials. Errors in blood measurements are likely 
to be distributed equally and unlikely to have introduced any 
systematic bias that could have affected the significance of 
the study results. Consistency across trials is determined by 
whether heterogeneity is present or not. During the analysis 
of the outcomes, two out of eight outcomes showed evidence 
of heterogeneity. To incorporate heterogeneity amongst 
studies, random effects meta-analysis was performed.
Potential biases in the review process
The objective and rationale of the review protocol was 
modified after careful study of previous trials carried out on 
the use of misoprostol in obstetrics. Although an extensive 
literature search was performed, only studies conducted in 
English were considered for the review. Some trials with 
imperative information may have been excluded due to the 
language barrier or because it had to be purchased. Two 
reviewers judged the relevance of each trial independently 
using a standardised data extraction form before the trials 
were included in the review to minimize bias. The Cochrane 
Collaboration methodological assessment tool was engaged 
in the assessment of the methodological quality of trials. There 
was no conflict of interest to be declared by the reviewers.
Agreements and disagreements with other study reviewers
To our knowledge, this review appears to be the first to 
perform a meta-analysis on studies that compared misoprostol 
to a placebo without the use of additional uterotonics. There 
is a need to carry out more randomised controlled trials 
on the subject.
Limitations of the study
The review focused mainly on studies comparing misoprostol 
to a placebo not in addition to other uterotonics; hence only 
three trials were included for analysis. This may result in 
other studies being excluded, which could have influenced 
the findings of this review. One study (Prata et al. 2005), that 
was initially included, was excluded after the methodological 
quality assessment. We only considered studies written in 
English. With adequate funding we would have conducted 
a search for studies written in other languages and those 
identified would have been sent for translation.
Recommendations
There is a need for large randomised controlled trials to 
evaluate the effectiveness of the use of misoprostol in the 
prevention and treatment of PPH. We accentuate that 
future studies should include using misoprostol alone in 
interventions - not in addition to other uterotonics, as most 
studies have been conducted. This could obscure the accurate 
effect of misoprostol.
Conclusion
The use of misoprostol was not associated with any significant 
reduction in the amount of blood loss. Studies included in 
the review were not large enough to evaluate the effects of 
misoprostol on maternal mortality in women with primary 
PPH. Because of the enormous potential impact of PPH on 
maternal health in poor countries, further research aiming 
to evaluate the effects of misoprostol on substantive health 
outcomes, its safety and the optimal route of administration 
and dosage are of the utmost urgency. Misoprostol is 
relatively cheap and easy to administer compared with 
injectable uterotonics (oxytocin and ergometrine), which are 
considered first-line treatment by WHO. Ergometrine and 
syntometrine are contraindicated in hypertensive pregnant 
women as they stimulate vasoconstriction and cause 
hypertension. Injectable uterotonics require skill, sterile 
syringes and alcohol swabs to be administered safely, are 
unstable in tropical conditions and call for special storage 
facilities to maintain efficacy. Misoprostol is devoid of these 
constraints and may therefore be an alternative treatment 
for PPH in developing countries where storage facilities and 
resources are limited.
Acknowledgements
We would like to acknowledge the library staff at Stellenbosch 
University for their assistance in retrieving the articles for this 
review. We would also like to thank SURMEPI for funding 
the authors so that they could attend advanced courses in 
Clinical Trials and systematic reviews and meta-analysis.
Competing interest
The authors declare that they have no financial or personal 
relationship(s) that may have inappropriately influenced 
them in writing this paper. 
Author contributions
K.M.O. (Stellenbosch University) did the review as 
part fulfillment of her Master’s degree in Nursing. O.K. 
(Stellenbosch University) was the supervisor. K.M.O. 
conducted the literature search and it was validated by O.K. 
guided the methodological process from conception to 
conclusion. K.M.O. wrote the manuscript with the guidance 
of O.K. and D.M. (Stellenbosch University) was the co-
supervisor and assisted in reviewing the systematic review.
References
Abou-Zahr, C., 2003, ‘The global burden of maternal death and disability’, British 
Medical Bulletin 67, 1–11. http://dx.doi.org/10.1093/bmb/ldg015
Amant, F., Spitz, B., Timmerman, D., Corremans, A. & Van Assche, F.A., 1999, 
‘Misoprostol compared with methylergometrine for the prevention of postpartum 
haemorrhage: A double-blind randomized trial’, British Journal of Obstetrics and 
Gynaecology 106, 1066–1070. http://dx.doi.org/10.1111/j.1471-0528.1999.
tb08115.x, PMid:10519433
Blum, J., Alfirevic, Z., Walraven, G., Weeks, A. & Winikoff, B., 2007, ‘Treatment of 
postpartum haemorrhage with misoprostol’, International Journal of Gynecology 
and Obstetrics 99, 202–205. http://dx.doi.org/10.1016/j.ijgo.2007.09.013, 
PMid:17961565
Original Research
doi:10.4102/curationis.36i1.57http://www.curationis.org.za
Page 10 of 10
Blum, J., Winikoff, B., Raghavan, S., Dabash, R., Ramadan, M.R., Dilbaz, B. et al., 2010, 
‘Treatment of post-partum haemorrhage with sublingual misoprostol versus 
oxytocin in women receiving prophylactic oxytocin: a double-blind, randomised, 
non-inferiority trial’, Lancet 375, 217–223. http://dx.doi.org/10.1016/S0140-
6736(09)61923-1
Bugalho, A., Daniel, A., Faundes, A. & Cunha, M., 2001, ‘Misoprostol for prevention of 
postpartum hemorrhage’, International Journal of Gynaecology and Obstetrics 73, 
1–6. http://dx.doi.org/10.1016/S0020-7292(01)00346-0
Cook, C.M., Spurrett, B. & Murray, H., 1999, ‘A randomized clinical trial comparing oral 
misoprostol with synthetic oxytocin or syntometrine in the third stage of labour’, 
Australia and New Zealand Journal of Obstetrics & Gynaecology 394, 414–419. 
http://dx.doi.org/10.1111/j.1479-828X.1999.tb03124.x
De Vos, A.S., 2005, ‘Qualitative data analysis and interpretation’, in A.S. De Vos, 
H. Strydom, C.B. Foche & C.S.L. Delport (eds.), Research at grassroots for the 
social sciences and human service professionals, 3rd edn, pp. 333–349,3rd edn., 
Pretoria, Van Schaik Publishers.
Deeks, J.J., Higgins, J.P.T. & Altman, D.G., 2006, ‘Analyzing and presenting results’, in 
J.P.T. Higgins, & S. Green (eds.), Cochrane Handbook for Systematic Reviews of 
Interventions 4.2.6., pp. 97–166, Chichester, John Wiley & Sons Ltd.
Derman, R.J., Kodkany, B.S., Goudar, S.S., Geller, S.E., Naik, V.A., Bellad, M.B., et al., 
2006, ‘Oral misoprostol in preventing postpartum haemorrhage in resource-poor 
communities: A randomised controlled trial’, Lancet 368, 1248–1253. http://dx.doi.
org/10.1016/S0140-6736(06)69522-6
El-Refaey, H., Nooh, R. & O’Brien, P., 2000, ‘The misoprostol third stage of labour study: 
A randomised controlled comparison between orally administered misoprostol 
and standard management’, British Journal of Obstetrics and Gynaecology 107, 
1104–1110. http://dx.doi.org/10.1111/j.1471-0528.2000.tb11108.x
El-Refaey, H., O’Brien, P., Morafa, W., Walder, J. & Rodeck, C., 1997, ‘Use of oral 
misoprostol in the prevention of postpartum haemorrhage’, British Journal of 
Obstetrics and Gynaecology 104, 336–339.
Fawcus, F. & Moodley, J., 2011, ‘Management of postpartum haemorrhage’, South 
African Journal of Obstetrics and Gynaecology 17, 1–3.
Fawole, A.O., Sotiloye, O.S., Hunyinbo, K.I., Umezulike, A.C., Okunlola, M.A. & Adekanle, 
D.A., 2010, ‘Misoprostol and routine uterotonics for prevention of postpartum 
hemorrhage: A double-blind, randomized, placebo controlled trial’, International 
Journal of Gynecolology and Obstetrics 112, 107–111. http://dx.doi.org/10.1016/j.
ijgo.2010.08.023, PMid:21130446
Gotzsche, P.C., 1989, ‘Methodology and overt and hidden bias in reports of 196 double 
blind trials of non-steroidal anti-inflammatory drugs in rheumatoid arthritis’, 
Controlled Clinical Trials 10, 3–56. http://dx.doi.org/10.1016/0197-2456(89)90017-2
Gülmezoglu, A. M., Fiona, F., Villar, J. & Hofmeyer, G.J., 2011, Prostaglandins for preventing 
postpartum Haemorrhage. Cochrane database systematic Review, 3, CD000494. 
Gülmezoglu, A.M., Villar, J., Ngoc, N.T., Piaggio, G., Carroli, G., Adetoro, L., et al., 2001, 
‘WHO collaborative group to evaluate misoprostol in the management of the 
third stage of labour. WHO multicentre randomised trial of misoprostol in the 
management of the third stage of labour’, Lancet 358, 689–695. PMid:11551574
Higgins, J.P.T. & Green, S., 2006, Cochrane Handbook for Systematic Reviews of 
Interventions 4.2.6, Chichester, John Wiley & Sons Ltd.
Hofmeyr, G.J., Nikodem, V.C., De Jager, M. & Drakely, A., 2001, ‘Side-effects of oral 
misoprostol in the third stage of labour-A randomised placebo-controlled trial’, 
South African Medical Journal 91, 432–435. PMid:11455810
Hofmeyr, G.J., Nikodem, V.C., de Jager, M. & Gelbart, B.R., 1998, ‘A randomised 
placebo controlled trial of oral misoprostol in the third stage of labour’, British 
Journal of Obstetrics and Gynaecology 105, 971–975. http://dx.doi.org/10.1111/ 
j.1471-0528.1998.tb10259.x, PMid:9763047
Hofmeyr, G.J., Ferreira, S. & Nikodem, V.C., 2004, ‘Misoprostol for treating postpartum 
haemorrhage: A randomized controlled trial’, BioMedical Centre Pregnancy 
Childbirth 4, 16. http://dx.doi.org/10.1186/1471-2393-4-16, PMid:15298718, 
PMCid:514549
Hofmeyr, J.G., Walraven, G., Gülmezoglu, M.A., Maholwana, B., Alfirevic, Z. & Villar, J., 
2005, Misoprostol to treat postpartum haemorrhage: a systematic review, BJOG: 
an International Journal of Obstetrics and Gynaecology, 112, 547–553.
Hofmeyr, G.J., Walraven, G. & Gülmezoglu, A.M., 2007, ‘Misoprostol to treat postpartum 
haemorrhage: A systematic review’, Journal of Obstetrics and Gynecology 112, 547–553.
Hofmeyr, G.J., Fawole, B., Mugerwa, K., Godi, P., Blignaut, Q., Mangesi, L, et al., 2010, 
‘Administration of 400 μg of misoprostol to augment routine active management 
of the third stage of labor’, International Journal of Gynecology and Obstetrics 
112, 98–102. http://dx.doi.org/10.1016/j.ijgo.2010.08.019, PMid:21130990
Hoj, L., Cardoso, P., Nielsen, B.B., Hvidman, L., Nielsen, J. & Aaby, P., 2005, ‘Effect of 
sublingual misoprostol on severe postpartum haemorrhage in a primary health 
centre in Guinea-Bissau: A randomised double blind clinical trial’, British Medical 
Journal 331, 723. http://www.unicef.org/infobycountry/southafrica_statistics.
html?q=printme, http://dx.doi.org/10.1136/bmj.331.7519.723, PMid:16195287, 
PMCid:1239973
Langenbach C., 2006, ‘Misoprostol in preventing postpartum hemorrhage: A meta-
analysis’, International Journal of Gynaecology and Obstetrics 92, 10–18. http://
dx.doi.org/10.1016/j.ijgo.2005.10.001, PMid:16309682
Lokugamage, A.U., Sullivan, K.R., Niculescu, O., Tigere, P., Onyangunga, F., El- Refaey, H., 
et al., 2001, ‘A randomized study comparing rectally administered misoprostol versus 
syntometrine combined with an oxytocin infusion for the cessation of primary post 
partum hemorrhage’, Acta Obstetrics and Gynecology Scandinavica 80, 835–839. 
http://dx.doi.org/10.1034/j.1600-0412.2001.080009835.x, PMid:11531635
McCormick, M.L., Sanghvi, H.C., Kinzie, B. & McIntosh, N., 2002, ‘Preventing postpartum 
haemorrhage in low-resource settings’, International Journal of Gynecology and 
Obstetrics 77, 267–275. http://dx.doi.org/10.1016/S0020-7292(02)00020-6
Millennium Development Goals Report (MDGs), 2010, viewed 24 January 2013, from 
http://www.un.org/millenniumgoals/pdf/MDG%20Report%202010%20En%20
r15%20-low%20res%2020100615%20-.pdf
Miller, S., Lester, F. & Hensleigh, P., 2004, ‘Prevention and treatment of postpartum 
hemorrhage: new advances for low-resource settings’, Journal of Midwifery 
Women’s Health 49, 283–292. http://dx.doi.org/10.1016/j.jmwh.2004.04.001, 
PMid:15236707
Mousa, H.A. & Alfirevic, Z., 2007, ‘Treatment for primary postpartum haemorrhage’, 
Cochrane Database of Systematic Reviews 1, CD003249. PMid:17253486
Ng, P.S., Chan, A.S., Sin, W.K., Tang, L.C., Cheung, K.B. & Yuen, P.M., 2001, ‘A multicentre 
randomized controlled trial of oral misoprostol and intramuscular syntometrine in 
the management of the third stage of labour’, Human Reproduction 16, 31–35. 
http://dx.doi.org/10.1093/humrep/16.1.31, PMid:11139532
Pillitteri, A. & Klweri, W., 2010, Maternal and childbearing nursing: Care of child bearing 
and child rearing family, Lippincott & William and Wilton Publishers, New York.
Prendiville, W.J., Elbourne, D. & McDonald, S, 2000, ‘Active versus expectant management 
in the third stage of labour’, Cochrane Database Systematic Review, CD000007.
Prata, N., Mbaruku, G., Campbell, M., Potts, M. & Vahidnia, F. 2005, Controlling postpartum 
hemorrhage after home births in Tanzania, International Journal of Gynaecology and 
Obstetetrics. 90, 51-55. http://dx.doi.org/10.1016/j.ijgo.2005.03.007
Rosenfield, A., Maine, D. & Freedman, L., 2006, ‘Meeting MDG-5: an impossible dream?’, 
Lancet 368, 1133. http://dx.doi.org/10.1016/S0140-6736(06)69386-0
Saving Mothers, 2002–2004, 2006, ‘The report on confidential enquiries into maternal 
deaths in South Africa. Third report’, Department of Health, South Africa, 68–95. 
Saving Mothers. 2002-2004, 2007, Third Report on Confidential Enquiries into Maternal 
Deaths in South Africa, Government Printer, Pretoria.
Saving Mothers 2005–2007, 2009, Fourth Report on Confidential Enquiries into 
Maternal Deaths in South Africa Expanded Executive Summary, National Committee 
on Confidential Enquiries into Maternal Deaths, Government Printer, Pretoria.
Sellers, P.M, 1995, Midwifery: A textbook and reference book for midwives in South 
Africa, 2nd edn., South Africa, Creda Press (Pty) Ltd.
Suberk, D.V., Fehr, P.M., Hösli, I. & Holzgreve, W., 1999, ‘Oral misoprostol for third stage 
of labor: A randomized placebo-controlled trial’, Elsevier Science Incorporation 92, 
255–258.
Tang, O.S., Schweer, H., Seyberth, H.W., Lee, S.W.H. & Ho, P.C., 2002, ‘Pharmacokinetics 
of different routes of administration of misoprostol’, Human Reproduction 17, 
332–336. http://dx.doi.org/10.1093/humrep/17.2.332, PMid:11821273
The United Nations Children’s Fund (UNICEF), 2008, Countdown to 2015. Maternal, 
Newborn and Child Survival. Tracking progress in maternal, newborn & child 
survival. The 2008 Report, UNICEF, New York.
The United Nations Children’s Emergency Funds (UNICEF), 2010, Trends in Maternal 
Mortality: 1990 to 2008, viewed 10 December 2010, from http://whqlibdoc.who.
int/publications/2010/9789241500265_eng.pdf
Tsu, V.D., & Shane, B., 2004, New and underutilized technologies to reduce maternal 
mortality: Call to action from a Bellagio workshop, International Journal of Gynaecology 
and Obstetrics 85, S83–S93. http://dx.doi.org/10.1016/j.ijgo.2004.02.011, 
PMid:15147857
Villar, J., Gulmezoglu, A.M., Hofmeyer, G.J. & Forna, F., 2002, ‘Systematic Review of 
randomised controlled trials of misoprostol to prevent Postpartum Haemorrhage’, 
Obstetrics and Gynecology 100, 1301–1312. http://dx.doi.org/10.1016/S0029-
7844(02)02371-2
Walraven, G., Dampha, Y., Bittaye, B., Sowe, M. & Hofmeyr, J., 2004, ‘Misoprostol in the 
treatment of postpartum haemorrhage in addition to routine management: A placebo 
randomized controlled trial’, British Journal of Obstetrics and Gynaecology 111, 
1014–1017. http://dx.doi.org/10.1111/j.1471-0528.2004.00217.x, PMid:15327620
Weeks, A. & Faúndes, A., 2007, ‘Misoprostol in obstetrics and gynecology’, International 
Journal of Gynaecology and Obstetrics 99, 156–159. http://dx.doi.org/10.1016/j.
ijgo.2007.09.003, PMid:17961572
Weeks, A., 2006, ‘Oral misoprostol for postpartum haemorrhage’, Lancet 368, 2123. 
http://dx.doi.org/10.1016/S0140-6736(06)69856-5
Widmer, M., Blum, J., Hofmeyr, G.J, Carroli, G., Abdel-Aleem, H. & Lumbiganon, P., 
2010, ‘Misoprostol as an adjunct to standard uterotonics for treatment of post-
partum hemorrhage: A multicentre, double-blind randomized trial’, Lancet 
375(9728), 1808–1813. http://dx.doi.org/10.1016/S0140-6736(10)60348-0
Winikoff, B., Dabash, R., Durocher, J., Darwish, E., Nguyen, T.N. & León, W., 2010, 
‘Treatment of post-partum haemorrhage with sublingual misoprostol versus 
oxytocin in women not exposed to oxytocin during labour: A double-blind, 
randomised, non-inferiority trial’, Lancet 375, 210–216. http://dx.doi.org/10.1016/ 
S0140-6736(09)61924-3
World Health Organization (WHO), 2000, World Health Report, 2000: Make Every 
Mother and Child Count, viewed 24 January 2013, from: http://www.who.int/
whr/2000/whr2000_en
World Health Organization, 2007, Maternal Mortality in 2005: Estimates developed by 
WHO, UNICEF, UNFPA and The World Bank, Geneva, Switzerland. 
World Health Organization (WHO), 2007, WHO recommendations for the prevention of 
postpartum haemorrhage, viewed 18 November 2010, from http://www.who.int/
making_pregnancy_safer/publications/WHORecommendationsforPPHaemorrhage.
pdf
Zuberi, N., Durocher, J., Sikander, R., Baber, N., Blum, J. & Walraven, G., 2008, ‘Misoprostol 
in addition to routine treatment of postpartum hemorrhage: A hospital-based 
randomized controlled-trial in Karachi, Pakistan’, BioMedical Centre Pregnancy 
Childbirth 8, 40. http://dx.doi.org/10.1186/1471-2393-8-40, PMid:18718007, 
PMCid:2529259
